Astraveus, providers of modular, microfluidic cell foundries for cell and gene therapy (CGT) manufacturing, has completed an oversubscribed €16.5 million Series Seed financing led by AdBio partners, co-syndicated with M Ventures, Johnson & Johnson Innovation – JJDC Inc., and Bpifrance Large Venture. Astraveus’ Lakhesys platform is an end-to-end cell foundry that uses deep process optimisation […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!
